Gemtesa 75 MG tablet 90S
Ended Awarded
- Contract number
- SPE2DB25FMZXF
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,095
Award facts
- Contract value 100% obligated
- $16,095.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,095.26 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical supplies to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates extensive experience delivering a comprehensive range of pharmaceutical products across multiple therapeutic domains through DLA's Medical Supply Chain. Gemtesa (mirabegron) is a beta-3 agonist used in the treatment of overactive bladder, reflecting the company's role in supplying specialized medications to support military and veteran healthcare needs. As a child contract under the SPE2DX master vehicle, this delivery order exemplifies the operational flexibility of the prime vendor model in addressing specific pharmaceutical requirements within the DLA's global medical supply network.
Quick answers
Who was awarded contract SPE2DB25FMZXF?
SPE2DB25FMZXF was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 9, 2025.
How much is contract SPE2DB25FMZXF worth?
The government has obligated $16,095 on SPE2DB25FMZXF.
Is contract SPE2DB25FMZXF an order under another contract?
Yes. SPE2DB25FMZXF is a delivery order under SPE2DB20D2104, an indefinite delivery contract.
Was contract SPE2DB25FMZXF competed?
The extent of competition for SPE2DB25FMZXF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award